Anupam Rasayan Reports Q3 Results And Acquisition Move

Anupam Rasayan India Limited (ARIL) reported consolidated unaudited results for the quarter ended December 31, 2025, showing total revenue of Rs5,145 million (mn), up 33 per cent year on year. Earnings before interest, tax, depreciation and amortisation including other income were Rs1,296 mn, reflecting growth of seven per cent and resulting in an EBITDA margin of 25.20 per cent for the quarter. Profit after tax for the quarter was Rs606 mn, up 12 per cent compared with the year earlier period.

The managing director said that for the nine months of FY26 the company delivered consolidated revenue of Rs17,297 mn and EBITDA of Rs4,024 mn, underscoring continued year on year growth. The company reported Q3 revenue consistent with quarterly performance and highlighted sustained cash generation and operational resilience. Management noted the quarter benefited from increased demand across key segments.

A key strategic development during the period was the signing of a definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States, which is expected to strengthen the group's global footprint. The acquisition was presented as enhancing capabilities in advanced custom synthesis and deepening access to regulated markets and innovator customers in North America. The move formed part of a stated plan to develop a global specialty chemical platform.

Anupam Rasayan is a custom synthesis and specialty chemicals manufacturer incorporated in 1984 with two verticals covering life science related specialty chemicals and other specialty chemicals such as polymer additives. The company supplies more than 75 domestic and international customers, including 31 multinational companies, and operates six manufacturing facilities in Gujarat with four facilities at Sachin in Surat and two at Jhagadia in Bharuch with an aggregate installed capacity of about 30,000 tonne (t) as of March 31, 2025. The group said it focuses on multistep synthesis and complex chemical reaction technologies while developing in-house processes to achieve cost optimisation.

Related Stories